Trademark Snap Shot ITU Unit Action
(Table presents the data on ITU Unit Action)

OVERVIEW

SERIAL NUMBER77256745FILING DATE08/16/2007
REG NUMBER0000000REG DATEN/A
REGISTERPRINCIPALMARK TYPETRADEMARK
INTL REG #N/AINTL REG DATEN/A
TM ATTORNEYSWAIN, MICHELE LYNN
L.O. ASSIGNED116

PUB INFORMATION

RUN DATE04/06/2011
PUB DATE07/08/2008
STATUS734-FIFTH EXTENSION - GRANTED
STATUS DATE04/05/2011
LITERAL MARK ELEMENTSSS

DATE ABANDONEDN/ADATE CANCELLEDN/A
SECTION 2FNOSECTION 2F IN PARTNO
SECTION 8NOSECTION 8 IN PARTNO
SECTION 15NOREPUB 12CN/A
RENEWAL FILEDNORENEWAL DATEN/A
DATE AMEND REGN/A


FILING BASIS

FILED BASISCURRENT BASISAMENDED BASIS
1 (a)NO1 (a)NO1 (a)NO
1 (b)YES1 (b)YES1 (b)NO
44DNO44DNO44DNO
44ENO44ENO44ENO
66ANO66ANO

NO BASISNONO BASISNO


MARK DATA

STANDARD CHARACTER MARKNO
LITERAL MARK ELEMENTSSS
MARK DRAWING CODE3-AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/LETTER(S)/NUMBER(S)
COLOR DRAWING FLAGNO

CURRENT OWNER INFORMATION

PARTY TYPE 20-OWNER AT PUBLICATION
NAME Sagent Holding Co.
ADDRESSBox 309GT
Ugland House South Church Street
Georgetown, 
ENTITY03-CORPORATION
CITIZENSHIPCayman Islands

GOODS AND SERVICES

INTERNATIONAL CLASS 005
          DESCRIPTION TEXT Pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, antihistamines, anti-infectives, anti-inflammatory agents, anticonvulsants, antidotes, antiemetics, antipsychotics, anxiolytics, blood modifiers, bronchodialators, cardiovasculars, diuretics, hormones, diluents, electrolytes, vitamins, oncolytics, immunosuppressive agents, transplantation agents, imaging agents, vascular targeting agents, and sensitizing agents for chemotherapy-resistant tumors; Pre-filled syringes sold filled with alkalizing agents; pre-filled syringes sold filled with analgesics; pre-filled syringes sold filled with anesthetics; pre-filled syringes sold filled with antacids; pre-filled syringes sold filled with anticholinergics; pre-filled syringes sold filled with antihistamines; pre-filled syringes sold filled with anti-infectives; pre-filled syringes sold filled with anti-inflammatory agents; pre-filled syringes sold filled with anticonvulsants; pre-filled syringes sold filled with antidotes; pre-filled syringes sold filled with antiemetics; pre-filled syringes sold filled with antipsychotics; pre-filled syringes sold filled with anxiolytics; pre-filled syringes sold filled with blood modifiers; pre-filled syringes sold filled with bronchodialators; pre-filled syringes sold filled with cardiovasculars; pre-filled syringes sold filled with diuretics; pre-filled syringes sold filled with hormones; pre-filled syringes sold filled with diluents; pre-filled syringes sold filled with electrolytes; pre-filled syringes sold filled with vitamins; pre-filled syringes sold filled with oncolytics; pre-filled syringes sold filled with immunosuppressive agents; pre-filled syringes sold filled with transplantation agents; pre-filled syringes sold filled with imaging agents; pre-filled syringes sold filled with vascular targeting agents; pre-filled syringes sold filled with sensitizing agents for chemotherapy-resistant tumors; Safety syringe devices sold filled with alkalizing agents; safety syringe devices sold filled with analgesics; safety syringe devices sold filled with anesthetics; safety syringe devices sold filled with antacids; safety syringe devices sold filled with anticholinergics; safety syringe devices sold filled with antihistamines; safety syringe devices sold filled with anti-infectives; safety syringe devices sold filled with anti-inflammatory agents; safety syringe devices sold filled with anticonvulsants; safety syringe devices sold filled with antidotes; safety syringe devices sold filled with antiemetics; safety syringe devices sold filled with antipsychotics; safety syringe devices sold filled with anxiolytics; safety syringe devices sold filled with blood modifiers; safety syringe devices sold filled with bronchodialators; safety syringe devices sold filled with cardiovasculars; safety syringe devices sold filled with diuretics; safety syringe devices sold filled with hormones; safety syringe devices sold filled with diluents; safety syringe devices sold filled with electrolytes; safety syringe devices sold filled with vitamins; safety syringe devices sold filled with oncolytics; safety syringe devices sold filled with immunosuppressive agents; safety syringe devices sold filled with transplantation agents; safety syringe devices sold filled with imaging agents; safety syringe devices sold filled with vascular targeting agents; safety syringe devices sold filled with sensitizing agents for chemotherapy-resistant tumors; Pharmaceuticals for treatment of cancer; pharmaceuticals to treat vascular diseases; Drug delivery systems sold as an integral component of drugs, namely, intradermal injection system for injection of anesthetics; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases; injectable drugs and therapeutic solutions for the treatment of psychotic disorders; injectable drugs and therapeutic solutions for the treatment of pain; injectable drugs and therapeutic solutions for the treatment of allergies; injectable drugs and therapeutic solutions for the treatment of infections; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease; injectable drugs and therapeutic solutions for the treatment of kidney disease; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies; injectable drugs and therapeutic solutions for the treatment of heartburn; injectable drugs and therapeutic solutions for the treatment of anxiety; injectable drugs and therapeutic solutions for immunosuppression; injectable drugs and therapeutic solutions for imaging; injectable drugs and therapeutic solutions for the treatment of seizures; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of psychotic disorders sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of allergies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of kidney disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of anxiety sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for immunosuppression sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of seizures sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS 005FIRST USE DATENONEFIRST USE IN COMMERCE DATENONECLASS STATUS6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATIONNO
COLORS CLAIMED STATEMENTColor is not claimed as a feature of the mark.
DESCRIPTION OF MARKThe mark consists of three three-dimensional letter "s's" in the form of a three-dimensional box.

PROSECUTION HISTORY

DATEENT CDENT TYPEDESCRIPTIONENT NUM
04/06/2011EXRAENOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED 040
04/05/2011EX5GSEXTENSION 5 GRANTED 039
03/28/2011EXT5SEXTENSION 5 FILED 038
03/28/2011EEXTITEAS EXTENSION RECEIVED 037
10/13/2010EXRAENOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED 036
10/12/2010EX4GSEXTENSION 4 GRANTED 035
09/30/2010EXT4SEXTENSION 4 FILED 034
09/30/2010EEXTITEAS EXTENSION RECEIVED 033
04/01/2010EXRAENOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED 032
03/31/2010EX3GSEXTENSION 3 GRANTED 031
03/25/2010EXT3SEXTENSION 3 FILED 030
03/25/2010EEXTITEAS EXTENSION RECEIVED 029
10/23/2009DPCCDDIVISIONAL PROCESSING COMPLETE 028
10/23/2009EX2GSEXTENSION 2 GRANTED 027
09/30/2009EXT2SEXTENSION 2 FILED 026
09/30/2009DRRRIDIVISIONAL REQUEST RECEIVED 025
10/19/2009AITUACASE ASSIGNED TO INTENT TO USE PARALEGAL 024
09/30/2009ERTDITEAS REQUEST TO DIVIDE RECEIVED 023
09/30/2009EEXTITEAS EXTENSION RECEIVED 022
03/30/2009EX1GSEXTENSION 1 GRANTED 021
03/30/2009EXT1SEXTENSION 1 FILED 020
03/30/2009EEXTITEAS EXTENSION RECEIVED 019
09/30/2008NOAMONOA MAILED - SOU REQUIRED FROM APPLICANT 018
07/08/2008PUBOAPUBLISHED FOR OPPOSITION 017
06/18/2008NPUBONOTICE OF PUBLICATION 016
06/04/2008PREVOLAW OFFICE PUBLICATION REVIEW COMPLETED 015
06/03/2008ALIEAASSIGNED TO LIE 014
06/03/2008CNSAPAPPROVED FOR PUB - PRINCIPAL REGISTER 013
05/27/2008TEMEITEAS/EMAIL CORRESPONDENCE ENTERED 012
05/27/2008CRFAICORRESPONDENCE RECEIVED IN LAW OFFICE 011
05/27/2008TROAITEAS RESPONSE TO OFFICE ACTION RECEIVED 010
11/27/2007GNRNONOTIFICATION OF NON-FINAL ACTION E-MAILED 009
11/27/2007GNRTONON-FINAL ACTION E-MAILED 008
11/27/2007CNRTRNON-FINAL ACTION WRITTEN 007
11/27/2007GNRNONOTIFICATION OF NON-FINAL ACTION E-MAILED 006
11/27/2007GNRTFNON-FINAL ACTION E-MAILED 005
11/27/2007CNRTRNON-FINAL ACTION WRITTEN 004
11/26/2007DOCKDASSIGNED TO EXAMINER 003
08/21/2007MDSCONOTICE OF DESIGN SEARCH CODE MAILED 002
08/20/2007NWAPINEW APPLICATION ENTERED IN TRAM 001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEYMarcia Ireland Rosenfeld
CORRESPONDENCE ADDRESSMARCIA IRELAND ROSENFELD
MCDONNELL BOEHNEN HULBERT & BERGOFF LLP
300 S WACKER DR STE 3200
CHICAGO, IL 60606-6709
DOMESTIC REPRESENTATIVENONE

PRIOR OWNER INFORMATION

PARTY TYPE 10-ORIGINAL APPLICANT
NAME Sagent Holding Co.
ADDRESSBox 309GT
Ugland House South Church Street
Georgetown, 
ENTITY03-CORPORATION
CITIZENSHIPCayman Islands